COLOMBO NICOLETTA

Olawaiye, A., Gladieff, L., O'Malley, D., Kim, J., Garbaos, G., Salutari, V., et al. (2025). Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. THE LANCET, 405(10496 (21–27 June 2025)), 2205-2216 [10.1016/S0140-6736(25)01040-2]. Detail

Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., et al. (2025). Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): Overall Survival Results From a Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial. OBSTETRICAL & GYNECOLOGICAL SURVEY, 80(2), 93-95 [10.1097/01.ogx.0001108096.71273.16]. Detail

Bogani, G., Caruso, G., Ray-Coquard, I., Ramirez, P., Concin, N., Ngoi, N., et al. (2025). Uterine leiomyosarcoma. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35(9) [10.1016/j.ijgc.2025.101992]. Detail

Oaknin, A., Monk, B., de Melo, A., Kim, H., Kim, Y., Lisyanskaya, A., et al. (2025). Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. EUROPEAN JOURNAL OF CANCER, 216(5 February 2025) [10.1016/j.ejca.2024.115146]. Detail

Bogani, G., Moore, K., Ray-Coquard, I., Lorusso, D., Matulonis, U., Ledermann, J., et al. (2025). Incorporating immune checkpoint inhibitors in epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 193(February 2025), 30-40 [10.1016/j.ygyno.2024.12.011]. Detail